technology appraisal in action
Download
Skip this Video
Download Presentation
TECHNOLOGY APPRAISAL IN ACTION

Loading in 2 Seconds...

play fullscreen
1 / 26

TECHNOLOGY APPRAISAL IN ACTION - PowerPoint PPT Presentation


  • 104 Views
  • Uploaded on

TECHNOLOGY APPRAISAL IN ACTION. Mrs Karen Samuels Programme Manager. WHO WHAT WHERE RELATED ORGANISATIONS CHALLENGES FUTURE. WMP MULTIDISCIPLINARY PARTNERSHIP. 1. WMIC 2. WeMeReC 3. WCM Therapeutics and Toxicology Centre 4. YCC Wales (Core WMP). ESTABLISHED 2002.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' TECHNOLOGY APPRAISAL IN ACTION' - brant


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
technology appraisal in action

TECHNOLOGY APPRAISAL IN ACTION

Mrs Karen Samuels

Programme Manager

slide2
WHO
  • WHAT
  • WHERE
  • RELATED ORGANISATIONS
  • CHALLENGES
  • FUTURE
wmp multidisciplinary partnership
WMP MULTIDISCIPLINARYPARTNERSHIP
  • 1. WMIC
  • 2. WeMeReC
  • 3. WCM Therapeutics and Toxicology Centre
  • 4. YCC Wales
  • (Core WMP)
established 2002
ESTABLISHED 2002
  • Appraised up to 8 High cost drugs per year
  • Strategic advice
  • Met 4 times per year
initial period 2002 2006
INITIAL PERIOD (2002-2006)
  • One step process
  • Public meeting
  • WMP appraisal team
  • One medical expert
  • Patient perspective
  • Two pharmaceutical company representatives
challenges
CHALLENGES
  • One step
  • Public nature
  • Medical expert
  • PIG submission
  • Health Economic issues
challenges continued
CHALLENGES (continued)
  • Small number of specialist medicines
  • Dependent on pharmaceutical Industry submission
  • Service links
  • Need
  • Commissioners (HCW)
  • Public demand e.g. trastusumab
april 2007
APRIL 2007
  • Second phase, 32 appraisals per year
  • 1. High cost
  • 2. Cancer drugs
  • 3. Cardiovascular drugs
modified process
MODIFIED PROCESS
  • Met with SMC
  • New sub group NMG
process
PROCESS
  • In the pipeline
  • MHRA licence (MA)
  • Company launch in the UK
  • Preliminary application (Form A)
  • Detailed application (Form B)
  • Patient Interest Groups
nmg role and membership
NMG ROLE AND MEMBERSHIP
  • Expert clinical & cost effectiveness advice to AWMSG
  • Broad spectrum membership
  • Lay representative
  • ABPI representative
  • Not in public
data considered
DATA CONSIDERED
  • WMP assessment report (AS AR)
  • Company response
  • Company’s detailed application (Form B)
  • Advice from Medical Expert (s)
  • Patient interest group submission
awmsg role and membership
AWMSG ROLE AND MEMBERSHIP
  • Consider strategic, societal, affordability aspects
  • Broader strategic
  • Senior NHS managers
  • Senior Finance directors
  • Lay representative
  • ABPI representative
data considered1
DATA CONSIDERED
  • NMG preliminary appraisal report (PAR)
  • Company response to the PAR
  • Patient Interest Group submissions
slide19
HOW?
  • In public
  • Announced at the meeting
  • Minister for Health and Social Services
related organisations
RELATED ORGANISATIONS
  • NICE/AWMSG/SMC
  • ABPI
  • CDG
  • All-Wales Cardiac and Cancer networks
  • Health Commission Wales
request for appraisal of cancer drugs
REQUEST FOR APPRAISAL OF CANCER DRUGS

Is drug/indication

licensed?

No

Yes

Is drug being

Appraised by NICE?

Refer to Cancer New Drugs

Group for appraisal

No

Yes

Await NICE

guidance

Refer to AWMSG

for appraisal

all wales cancer drugs group
ALL WALES CANCERDRUGS GROUP
  • No backlog
  • AWCDG to help prioritise
  • Engaging network
    • Oncologists
    • Oncology pharmacists
  • Horizon scanning
slide23
England and Wales - NICE

takes precedence

  • Wales - AWMSG

Local MTC’s

slide24

SCOTLAND

SMC

  • Streamlined process
  • Similar paperwork
  • Simultaneous submissions
slide25
ABPI
  • Users Group
  • Regular
  • Input process
future
FUTURE
  • Extend to all new medicines?
  • Increased links with patient groups
  • Further collaboration with NICE/SMC
  • Review process after 2 cycles
ad